Three straight days of closing ahead has the AEterna Zentaris chart on watch for continued upward pressure. Shares rose 8.5 percent on Tuesday to close near the high of the day on increased volume, which is a bullish sign as the stock nears resistance. Shares traded as low as $1.75 last week, but have recovered to close on Tuesday at $2.16 on volume of 1.1 million.
On Monday, the company announced that perifosine, its oral AKT inhibitor, combined with temsirolimus, was well tolerated in an investigator driven Phase 1 clinical trial in recurrent or progressive malignant glioma. Data were presented over the weekend by Thomas J. Kaley, MD, Director, Neuro-Oncology Fellowship Program at Memorial Sloan-Kettering Cancer Center, during a poster session at the Society of Neuro-Oncology annual meeting in Washington D.C.
Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. Its pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products.
Aeterna Zentaris (AEZS) Stock Quote and News:
Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.
0 comments
Add your comment
Commenting is allowed only for registered users.